Fig. 4.

Increased use of neoadjuvant hormonal therapy in March-June 2020 in patients with lower stage tumors. Difference between the observed and predicted number of operated patients with invasive breast cancer diagnosed in January-September 2020 who received primary surgery or NAT followed by surgery, corrected for the total decline in diagnosis, by month of incidence (A), age group (B), and clinical stage (C). Difference between the observed and predicted number of patients with invasive breast cancer diagnosed in January-September 2020 who received each type of neoadjuvant systemic therapy, corrected for the total change in number of operated patients who received neoadjuvant systemic therapy, by clinical stage (D). NAT = neoadjuvant systemic therapy. NACT = neoadjuvant chemotherapy. NAHT = neoadjuvant hormonal therapy. NATT = neoadjuvant targeted therapy. Error bars represent 95% confidence intervals. When the 95% confidence interval does not contain 0, the observed number of cases is significantly different from what would be expected. Patients with multiple invasive or breast tumors were excluded from this analysis